FDA Approves New Interchangeable Biosimilar to Pertuzumab By Ogkologos - December 3, 2025 308 0 Facebook Twitter Google+ Pinterest WhatsApp Approval is based on comparisons across a broad range of structural and functional product quality attributes Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Zanubrutinib’s Approval Improves Targeted Treatment for CLL January 27, 2023 Tomorrow is National Prescription Drug Take-Back Day! April 29, 2022 Efficacy of Romiplostim In the Treatment and Prevention of Recurrence of... March 26, 2026 EMA Adopts a Positive Opinion for Biosimilar Denosumab May 28, 2025 Load more HOT NEWS “Selfless and Incredible” Mother Leaves Behind Five Children After Battling Breast... ESMO Asia Congress 2023, 1-3 December 2023, Singapore ESMO 2025: A Glimpse Into the Congress Programme, Berlin, Germany, 17-21... Can Some People with Breast Cancer Safely Skip Lymph Node Radiation?
